Shanghai, Shanghai, China The main office of represented VC is situated in the Shanghai. The fund was located in Asia if to be more exact in China.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Morningside Technology Ventures, startups are often financed by University Ventures, Morningside Group, Top Line Growth Capital. The meaningful sponsors for the fund in investment in the same round are University Ventures, Tamarisc Ventures, Topline Capital. In the next rounds fund is usually obtained by University Ventures, Tudor Growth Equity, The Exxel Group.
Among the most popular portfolio startups of the fund, we may highlight Rockley Photonics, Jitjatjo, Ignition Design Labs. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Education, Internet. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The real fund results show that this VC is 30 percentage points more often commits exit comparing to other companies. Opposing the other organizations, this Morningside Technology Ventures works on 19 percentage points less the average amount of lead investments. The top activity for fund was in 2019.
Related Funds
| Fund Name | Location |
| Century Financial Partners | - |
| Even | China, Jiangsu, Suzhou |
| Fomocraft Ventures | - |
| Osprey Capital | Illinois, United States, Wilmette |
| Rivington Capital Partners | Houston, Texas, United States |
| Sino Biopharmaceutical | China, Hong Kong, Hong Kong Island |
| Sony Music Entertainment | New York, New York, United States |
| Toyo Engineering | Chiba, Chiba Prefecture, Japan |
| Trentino Sviluppo | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ENYO Pharma | $46M | 03 Jan 2024 | Lyon, Auvergne-Rhône-Alpes, France | ||
Epigenic Therapeutics | $32M | 29 Aug 2023 | Shanghai, Shanghai, China | ||
GaeaStar | $6M | 06 Apr 2023 | Berlin, Berlin, Germany | ||
Phage Pharm | $13M | 01 Mar 2023 | Qingdao Shi, Shandong, China | ||
Resilience Lab | $15M | 17 Nov 2022 | New York, New York, United States | ||
Valitor | $28M | 05 Oct 2022 | Berkeley, California, United States | ||
AdvanCell | $13M | 23 Aug 2022 | Sydney, New South Wales, Australia | ||
Epigenic Therapeutics | $20M | 07 Aug 2022 | Shanghai, Shanghai, China | ||
Casana | $40M | 21 Jan 2022 | Rochester, New York, United States |
– Hummingbird Bioscience from Singapore develops precision therapies against hard-to-drug targets to improve treatment outcomes.
– Series C $125m round brings company valuation to more than $1b.
– The round was led by Novo Holdings with participation from new investors – Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ENYO Pharma | $46M | 03 Jan 2024 | Lyon, Auvergne-Rhône-Alpes, France | ||
Epigenic Therapeutics | $32M | 29 Aug 2023 | Shanghai, Shanghai, China | ||
GaeaStar | $6M | 06 Apr 2023 | Berlin, Berlin, Germany | ||
Phage Pharm | $13M | 01 Mar 2023 | Qingdao Shi, Shandong, China | ||
Resilience Lab | $15M | 17 Nov 2022 | New York, New York, United States | ||
Valitor | $28M | 05 Oct 2022 | Berkeley, California, United States | ||
AdvanCell | $13M | 23 Aug 2022 | Sydney, New South Wales, Australia | ||
Epigenic Therapeutics | $20M | 07 Aug 2022 | Shanghai, Shanghai, China | ||
Casana | $40M | 21 Jan 2022 | Rochester, New York, United States |
